Specialized Focus ProSciento's exclusive focus on diabetes, obesity, and NAFLD/NASH positions it as a highly specialized CRO within the metabolic disease sector, making it an attractive partner for pharmaceutical companies targeting these areas.

Strong Industry Recognition Receiving the 2023 Innovation Award from The Liver Coalition of San Diego enhances ProSciento’s credibility and visibility, opening doors for collaborations with organizations and funders prioritizing liver health and innovative research.

Strategic Partnerships Active partnerships with leading organizations like the American Diabetes Association and Breakthrough T1D demonstrate ProSciento’s strong ties within the diabetes and metabolic communities, which can facilitate referral opportunities and joint ventures.

Leadership Expansion Recent appointments of senior executives, including a new COO and VP of People, indicate an organization investing in leadership and operational growth—potential signals for scalable service offerings and capacity expansion.

Market Positioning ProSciento’s niche specialization and active participation in industry forums, such as the Metabolic Continuum Roundtable, suggest it is well-positioned to attract clients seeking expert clinical trial services in metabolic research, creating potential sales opportunities through targeted outreach.